June 4, 2020 /

Capricor’s HOPE-2 Final 12-Month Data (June 3, 2020)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Webinar: Capricor’s HOPE-2 Final 12-Month Data (June 3, 2020)

Capricor Therapeutics recently announced positive final 12-month results from the HOPE-2 Trial. HOPE-2 was a randomized, double-blind, placebo-controlled study focused on later-stage Duchenne patients. On June 3, 2020, Capricor joined PPMD for a webinar to discuss Capricor’s HOPE-2 clinical program.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo